NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

現實世界證據 (RWE) 解決方案的全球市場:成長,趨勢,預測

Real-World Evidence Solutions Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 708592
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
現實世界證據 (RWE) 解決方案的全球市場:成長,趨勢,預測 Real-World Evidence Solutions Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球現實世界證據 (RWE) 解決方案市場的相關調查,市場機會和趨勢,成長及阻礙因素,各零組件、治療領域、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各零件
  • 各治療領域
  • 各終端用戶
  • 各地區

第6章 競爭情形

  • 企業簡介
    • Clinigen
    • Icon PLC
    • IBM
    • Iqvia
    • Oracle
    • Parexel
    • Perkinelmer
    • Pharmaceutical Product Development
    • SAS Institute
    • Syneos Health

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64347

The real-world evidence solutions market will show rapid growth due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases and delays in drug development and the subsequent increase in development costs.

Pharmaceutical companies take several years to introduce a new drug molecule to market, and they invest billions in research and development with a low probability of success. To shorten the drug development cycles, pharma research centers need a clear insight on treatment options that work in a wide population compared to few patient pools in clinical trials. The use of real-world evidence (RWE) insights is thus found increasing as pharma and biotech companies realize that RWE can be important in drug development and life-cycle management and also increase efficiency in innovation and cost of clinical trials.

The big pharmaceutical companies are found using a clinico-genomic database with tumor sequencing information for cancer discovery studies and targeted drug development. Companies are thus able to broaden their indication range and conduct a small number of clinical trials for the rare biomarker-defined population. Thus it indicates the growth of real-world evidence solutions market, during the forecast period.

In addition, the real-world data sets are widely adopted by end-users for RWE for various applications such as drug development & approvals, market access & reimbursement/coverage decisions, clinical decision-making, and medical device development & approvals, among others, that helps in the growth of the overall market.

Key Market Trends

Oncology is Anticipated to be the Dominant Segment During the Forecast Period

Based on the therapeutic area, the real-world evidence market is broadly categorized into oncology, immunology, neurology, cardiovascular disease, and other therapeutic areas the oncology segment has been accounted for the largest share of the real-world evidence market. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide. According to the World Health Organization (WHO), Cancer is the second leading cause of death across the globe, with an estimated 9.6 million deaths in 2018. There is also an increasing personalized medicine and a more precise requirement for oncology, which is expected to further fuel the market growth.

North America Region Holds the Largest Market Share of Real-world Evidence Solutions Market

North America has been accounted for the largest share of the real-world evidence market followed by Europe and the Asia Pacific. There has been a presence of a favorable regulatory environment, a high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, these factors are responsible for the major share of North America in the global real-world evidence market.

The US is expected to dominate the North American market, owing to a high demand in clinical research activities, which is one of the important factors augmenting the demand of real-world evidence solutions market in the North America region.

Competitive Landscape

Product launches, partnerships, collaborations, agreements, and market expansions are the key strategies adopted by players to grow and expand their presence in the real-world evidence solutions market. Some of the key players in the market includes IQVIA, ICON, PAREXEL, Oracle Corporation and Clinigen Group among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Shift From Volume- to Value-based Care
    • 4.2.2 Increasing Aging Population and Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 Unwillingness to Rely on Real-world Studies
    • 4.3.2 Lack of Standards
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Component
    • 5.1.1 Claims Data
    • 5.1.2 Clinical Settings Data
    • 5.1.3 Patient-Powered Data
    • 5.1.4 Pharmacy Data
    • 5.1.5 Others
  • 5.2 By Therapeutic Area
    • 5.2.1 Oncology
    • 5.2.2 Immunology
    • 5.2.3 Neurology
    • 5.2.4 Cardiovascular Disease
    • 5.2.5 Other Therapeutic Areas
  • 5.3 By End User
    • 5.3.1 Healthcare Payers
    • 5.3.2 Healthcare Providers
    • 5.3.3 Pharmaceutical & Medical Device Companies
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinigen Group
    • 6.1.2 Icon PLC
    • 6.1.3 IBM
    • 6.1.4 IQVIA
    • 6.1.5 Oracle Corporation
    • 6.1.6 Parexel International
    • 6.1.7 PerkinElmer, Inc.
    • 6.1.8 Pharmaceutical Product Development (PPD, Inc)
    • 6.1.9 SAS Institute
    • 6.1.10 Syneos Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS